Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib plus abiraterone versus placebo plus abiraterone in post-docetaxel metastatic castration-resistant prostate cancer
2013-003520-37Phase 2Unknown
- Sponsor
- AstraZeneca
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Olaparib + abiraterone + prednisolone with Placebo + abiraterone + prednisolone (2 arms). Primary endpoint: Safety and tolerability of olaparib with abiraterone and prednisolone. Status: unknown.
02
Drugs
olaparib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2013-003520-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003520-37.